Press Releases + News

Date	Title and Summary	View
Toggle SummaryOct 07, 2015	Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference	View HTML Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference 22.8 KB
Toggle SummaryOct 06, 2015	Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" Interview Airs October 6, 2015, Hosted by Bob "Sully" Sullivan, 3:00pm ET/ 12:00pm PT/ 2:00pm CT	View HTML Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" 18.8 KB
Toggle SummarySep 24, 2015	Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 Proof-of-Concept Study to Determine Safety and Efficacy in 10 Patients With Moderate-to-Severe Plaque Psoriasis	View HTML Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 89.7 KB
Toggle SummarySep 22, 2015	Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference	View HTML Galectin Therapeutics to Present at 2015 Ladenburg Thalmann Healthcare Conference 19.3 KB
Toggle SummarySep 16, 2015	Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis Second Trial in GR-MD-02 Phase 2 Program Features Non-Invasive Endpoints and Shorter Treatment Duration; Data Readout Expected in the Third Quarter of 2016	View HTML Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis 28.1 KB
Toggle SummarySep 08, 2015	Galectin Therapeutics to Participate in Three Investment Conferences in September	View HTML Galectin Therapeutics to Participate in Three Investment Conferences in September 13.8 KB
Toggle SummaryAug 13, 2015	Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases Broad Coverage Includes Use of Various Pectin Compounds for Chronic Kidney Disease Associated with the Development of Fibrosis, Established Kidney Fibrosis, Chronic Lung Disease Associated with the Development of Fibrosis and Established Lung Fibrosis	View HTML Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 23.6 KB
Toggle SummaryAug 10, 2015	Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results	View HTML Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results 24 KB
Toggle SummaryJul 15, 2015	Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development	View HTML Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development 23.6 KB
Toggle SummaryJun 29, 2015	Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis First Five Patients Screened	View HTML Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis 30.9 KB